HenryBKoonJr.MD

Oncology • Lawrenceville, NJ

Hematologic Oncology, Melanoma, Sarcoma

Clinical Trial Lead, Melanoma

Join to view full profile

Dr. Koon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Koon's full profile

Already have an account?

Office
Bristol Myers Squibb
3401 Princeton Pike
Lawrenceville, NJ 08648
Is this information wrong?

Summary

Dr. Henry Koon is an oncologist in Lawrenceville, NJ. He received his medical degree from University of Mississippi School of Medicine and has been in practice 23 years. He specializes in hematologic oncology and is experienced in sarcomas, melanoma and cutaneous malignancies.

Education & Training

University of Mississippi Medical CenterResidency, Internal Medicine, 1994 - 1997
University of Mississippi School of MedicineClass of 1994

Certifications & Licensure

OH State Medical License 2007 - 2024

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma Start of enrollment: 1999 Feb 01
Completed
Phase 1
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2003 May 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2005 Jun 01
Completed
Phase 2
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma Start of enrollment: 2009 Jul 01
Terminated
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

253 citations
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Dean F Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, T. Lebret, Shahrokh F. Shariat, Se ...> ;The New England Journal of Medicine. 2021 Jun 2
10 citations
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid, Laura F. Hutchins, Jeffrey A. Sosman, Harriet M. Kluger, Zeynep Eroglu, Henry B. ...> ;Journal for Immunotherapy of Cancer. 2021 May 1
51 citations
Evolving impact of long-term survival results on metastatic melanoma treatment.
Olivier Michielin, Michael B. Atkins, Henry B. Koon, Reinhard Dummer, Paolo A. Ascierto> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
17 citations
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Nikhil I. Khushalani, Adi Diab, Paolo A. Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry B. Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich, William J....> ;Future Oncology. 2020 Jul 29
3 citations
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors
Jennifer R. Eads, Smitha S. Krishnamurthi, Joel N. Saltzman, Joseph A. Bokar, P. Savvides, Neal J. Meropol, Joseph Gibbons, Henry B. Koon, Neelesh Sharma, Lisa Rogers,...> ;Investigational New Drugs. 2021 Feb 1
91 citations
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen, Omid Hamid, Laura F. Hutchins, Jeffrey A. Sosman, H. Kluger, Zeynep Eroglu, Henry B. Ko...> ;Journal of Clinical Oncology. 2020 Feb 20
35 citations
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
Pooja H. Rambhia, Barbara Reichert, Jeffrey F. Scott, Ashley Feneran, Jordan Kazakov, Kord Honda, Henry B. Koon, Meg R. Gerstenblith> ;International Journal of Clinical Oncology. 2019 Jul 18
178 citations
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Margaret von Mehren, R Lor Randall, Robert S Benjamin, Sarah Boles, Marilyn M Bui, Kristen N Ganjoo, Suzanne George, Ricardo J Gonzalez, Martin J Heslin, John M Kane, ...> ;Journal of the National Comprehensive Cancer Network. 2018 May 1
75 citations
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E...
Kevin Kalinsky, Sandra J. Lee, Krista M. Rubin, Donald P. Lawrence, Anthony J. Iafrarte, Darell R. Borger, Kim Margolin, Mario M. Leitao, Ahmad A. Tarhini, Henry B. Ko...> ;Cancer. 2017 Jul 15
Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
William D. Longhurst, Kord Honda, Henry B. Koon, Meg R. Gerstenblith> ;The American Journal of Dermatopathology. 2016 Oct 1
47 citations
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy H. Guthrie, Sajeve S. Thomas, Steven J. O'Day, Montaser Shaheen, Bin Zhang, Stephen Francis, F. Step...> ;Journal for Immunotherapy of Cancer. 2016 Aug 16
81 citations
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
Margaret von Mehren, R Lor Randall, Robert S Benjamin, Sarah Boles, Marilyn M Bui, Ernest U Conrad 3rd, Kristen N Ganjoo, Suzanne George, Ricardo J Gonzalez, Martin J ...> ;Journal of the National Comprehensive Cancer Network. 2016 Jun 1
2 citations
Parotid melanoma of unknown primary
Jeffrey F. Scott, Cheryl L. Thompson, Ritva Vyas, Kord Honda, Chad A. Zender, Rod Rezaee, Pierre Lavertu, Henry B. Koon, Kevin D. Cooper, Meg R. Gerstenblith> ;Journal of Cancer Research and Clinical Oncology. 2016 Apr 13
1 citations
Scurvy in a patient on vemurafenib
Meg R. Gerstenblith, Tatyana A. Petukhova, Henry B. Koon> ;JAAD Case Reports. 2015 Jan 1
21 citations
Current systemic therapies for melanoma.
Darren M. Palathinkal, Timmie R. Sharma, Henry B. Koon, Jeremy S. Bordeaux> ;Dermatologic Surgery. 2014 Sep 1
101 citations
Update on primary mucosal melanoma.
Joselin D. Tacastacas, Julie Bray, Yoon K. Cohen, Joshua Arbesman, Julian Kim, Henry B. Koon, Kord Honda, Kevin D. Cooper, Meg R. Gerstenblith> ;Journal of the American Academy of Dermatology. 2014 Aug 1
15 citations
Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers
Kriti Mittal, Henry B. Koon, Paul Elson, Pierre L. Triozzi, Afshin Dowlati, Ernest C. Borden, Brian I. Rini> ;Cancer Biology & Therapy. 2014 May 19
21 citations
What is the role of chemotherapy in the treatment of melanoma
Ahmed I. Megahed, Henry B. Koon> ;Current Treatment Options in Oncology. 2014 Mar 6
1 citations
Delayed response in ipilimumab therapy.
Ahmed I. Megahed, Peter Faulhaber, Tycel Phillips, Henry B. Koon> ;The Journal of Community and Supportive Oncology. 2014 Mar 1
67 citations
Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042
Henry B. Koon, Susan E. Krown, Jeannette Y. Lee, Kord Honda, Suthee Rapisuwon, Zhenghe Wang, David M. Aboulafia, Erin Reid, Michelle A. Rudek, Bruce J. Dezube, Ariela Noy> ;Journal of Clinical Oncology. 2014 Feb 10
10 citations
Acneiform eruptions associated with vemurafenib
Tatyana A. Petukhova, Roberto A. Novoa, Kord Honda, Henry B. Koon, Meg R. Gerstenblith> ;Journal of the American Academy of Dermatology. 2013 Mar 1
20 citations
Vasculitis and panniculitis associated with vemurafenib
Roberto A. Novoa, Kord Honda, Henry B. Koon, Meg R. Gerstenblith> ;Journal of the American Academy of Dermatology. 2012 Dec 1
13 citations
CpG Methylation as a Tool to Characterize Cell-Free Kaposi Sarcoma Herpesvirus DNA
Meir Shamay, Nicholas Hand, M. Victor Lemas, Henry B. Koon, Susan E. Krown, John Wrangle, Prashant Desai, Juan Carlos Ramos, Richard F. Ambinder> ;The Journal of Infectious Diseases. 2012 Apr 1
5 citations
Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement
Derek V. Chan, Pamela Summers, Marie S. Tuttle, Kevin D. Cooper, Brenda W. Cooper, Henry B. Koon, Kord Honda> ;Journal of the American Academy of Dermatology. 2011 Sep 1
Phase II AIDS Malignancy Consortium trial of imatinib in AIDS-associated Kaposi's sarcoma (KS).
Koon HB, Honda K, Lee JY, Noy A> ;J. Clin. Oncol.. 2011-05-20
Join now to see all

Press Mentions

Leap Therapeutics Presents Data from Phase 1 Study of GITR AgonistNovember 12th, 2016
$Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting$
Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual MeetingJune 5th, 2016